Imatinib: is 400 mg the best starting dose for CML patients in early chronic phase?An abstract is unavailable.doi:10.1097/01.OTU.0000394188.60634.5aCarlsonRobert HOncology Times Uk
Imatinib has become the treatment of choice for most with CML. The standard dose (SD) for CP CML is 400 mg daily, but pre-clinical and clinical observations suggest that higher doses (HD) may be more effective. We have treated 222 with previously untreated CML in early CP with imatinib ...
-Patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after the failure of interferon-alpha therapyUsual Adult Dose of Imatinib for Acute Lymphoblastic Leukemia:600 mg orally daily Use: For relapse...
The ASH meeting featured another agent-AMN107 (Novartis), which is 10 to 50 times more potent than imatinib. In a phase I clinical trial, 119 patients who were resistant to imatinib received AMN107; in some cases the dose was increased up to 12-fold with no problems. ...
Based on the recovery of compound(s) after an oral [14C]-labelled dose of imatinib, approximately 81% of the dose was recovered within 7 days in faeces (68% of dose) and urine (13% of dose). Unchanged imatinib accounted for 25% of the dose (5% urine, 20% faeces), the remainder ...
Early molecular response to imatinib in CP-CML patients: the significance of early dose intensity and OCT-1 activity in responders and efficacy of dose escalation and switch to nilotinib in non-responders. ASH Annu Meet Abstr 2012; 120: 693. Google Scholar Davies A, Jordanides NE, Gianno...
Early molecular response to imatinib in CP-CML patients: the significance of early dose intensity and OCT-1 activity in responders and efficacy of dose escalation and switch to nilotinib in non-responders. ASH Annu Meet Abstr 2012; 120: 693. Google Scholar Davies A, Jordanides NE, Gianno...
He added that the findings may obviate earlier concerns about high-dose therapy with stem-cell support. With the broadened options that imatinib provides, "now it [stem-cell support] will be rarely used," he said. "This study confirms all of the early results and shows that this drug may...
. Diagnosis of accelerated phase CML was based on karyotypic evolution (n = 9) and hematologic criteria (n = 18). All patients were begun on 600 mg/day of imatinib mesylate. Dose reductions to 400 mg/day and then 300 mg/day were prescribed for an absolute neutrophil count (ANC) of <...
Starting dose 400 mg/day ie, MDS/MP, ASM, HES/CEL, GIST, and chronic phase Ph+ CML ANC <1 x 10^9/L and/or platelets <50 x 10^9/L: Hold until ANC ≥1.5 x 10^9/L and platelets ≥75 x 10^9/L Resume therapy at original starting dose For recurrence: Hold until ANC ≥1.5 ...